Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impaired innate and adaptive immune responses to BNT162b2 SARSCoV-2 vaccination in systemic lupus erythematosus [CTD]

ABSTRACT: We measued IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in SLE and healthy controls who received the BNT162b2 vaccine.

ORGANISM(S): Triticum aestivum Escherichia coli Bos taurus Sus scrofa Spodoptera frugiperda Homo sapiens Capra hircus

PROVIDER: GSE260478 | GEO | 2024/03/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Impaired innate and adaptive immune responses to BNT162b2 SARSCoV-2 vaccination in systemic lupus erythematosus [ACA]

Project description:We measued IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in SLE and healthy controls who received the BNT162b2 vaccine.

2024-03-02 | GSE260475 | GEO

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [CTD]

Project description:We used protein arrays to measure IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in patients with non-COVID-19 infections such as influenza

2023-01-12 | GSE222764 | GEO

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness [ACA]

2023-01-12 | GSE222760 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Autoantigen V1]

Project description:We developed three different protein arrays to measure IgG autoantibodies associated with Connective Tissue Diseases (CTDs), Anti-Cytokine Antibodies (ACA), and anti-viral antibody responses in 147 hospitalized COVID-19 patients in three different centers.

2021-07-24 | GSE180737 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [viral]

2021-07-24 | GSE180742 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Unpaired Cytokine and Chemokine]

2021-07-24 | GSE180741 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Paired Cytokine]

2021-07-24 | GSE180740 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Unpaired Autoantigen V2]

2021-07-24 | GSE180739 | GEO

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 [Autoantigen V2]

2021-07-24 | GSE180738 | GEO

Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

Project description:Understanding the immune responses to SARS-CoV-2 vaccination is critical to optimizing vaccination strategies for individuals with autoimmune diseases, such as systemic lupus erythematosus (SLE). Here, we comprehensively analyzed innate and adaptive immune responses in 19 patients with SLE receiving a complete 2-dose Pfizer-BioNTech mRNA vaccine (BNT162b2) regimen compared with a control cohort of 56 healthy control (HC) volunteers. Patients with SLE exhibited impaired neutralizing antibody production and antigen-specific CD4+ and CD8+ T cell responses relative to HC. Interestingly, antibody responses were only altered in patients with SLE treated with immunosuppressive therapies, whereas impairment of antigen-specific CD4+ and CD8+ T cell numbers was independent of medication. Patients with SLE also displayed reduced levels of circulating CXC motif chemokine ligands, CXCL9, CXCL10, CXCL11, and IFN-γ after secondary vaccination as well as downregulation of gene expression pathways indicative of compromised innate immune responses. Single-cell RNA-Seq analysis reveals that patients with SLE showed reduced levels of a vaccine-inducible monocyte population characterized by overexpression of IFN-response transcription factors. Thus, although 2 doses of BNT162b2 induced relatively robust immune responses in patients with SLE, our data demonstrate impairment of both innate and adaptive immune responses relative to HC, highlighting a need for population-specific vaccination studies.

2024-03-01 | GSE250024 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data